{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:25:48Z","timestamp":1787066748459,"version":"build-2736575974"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":426,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>LMNA-related dilated cardiomyopathy (DCM) is a rare disease with an incompletely defined phenotype. The phase 3 REALM-DCM trial evaluated a potential disease-modifying therapy for LMNA-related DCM but was terminated due to futility without safety concern. This study utilized pooled data from REALM-DCM to descriptively characterize the phenotype and progression of LMNA-related DCM in a contemporary cohort of patients using common heart failure (HF) measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>REALM-DCM enrolled patients with stable LMNA-related DCM, an implanted cardioverter defibrillator or cardiac resynchronization therapy defibrillator, and New York Heart Association (NYHA) Class II\/III HF symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between 2018 and 2022, 77 patients took part in REALM-DCM. The median patient age was 53 years (range: 23\u201372), and 57% were male. Overall, 88% of patients had a pathogenic or likely pathogenic LMNA variant, and 12% had a variant of uncertain significance with a concordant phenotype. Among patients with confirmed sequencing, 55% had a missense variant. Atrial fibrillation was present in 60% of patients; 79% of all patients had NYHA Class II and 21% had NYHA Class III HF symptoms at baseline. Median (range) left ventricular ejection fraction (LVEF), 6 min walk test (6MWT) distance, Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS) score and N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration at baseline were 42% (23\u201362), 403 m (173\u2013481), 67 (18\u201397) and 866 pg\/mL (57\u20135248), respectively. LVEF, 6MWT distance and KCCQ-OS score were numerically lower in patients who had NYHA Class III versus II symptoms at baseline (LVEF: 38% vs. 43%; 6MWT distance: 326 vs. 413 m; and KCCQ-OS score: 43 vs. 70), whereas NT-proBNP concentration was higher (1216 vs. 799 pg\/mL). Median follow-up was 73 weeks (range: 0.4\u2013218; 73 in NYHA Class II and 75 in NYHA Class III). Patients displayed variable change from baseline in 6MWT, KCCQ-OS and NT-proBNP values during follow-up. Overall, 25% of patients experienced ventricular tachycardia, and 8% had ventricular fibrillation. Ten (13%) patients met the composite endpoint of worsening HF (adjudicated HF-related hospitalization or urgent care visit) or all-cause death; six had NYHA Class II and four had NYHA Class III at baseline. All-cause mortality occurred in 6 (8%) patients; three had NYHA Class II and three had NYHA Class III symptoms at baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Findings confirm the significant morbidity and mortality associated with LMNA-related DCM despite the standard of care management. Typical measures of HF, including 6MWT distance, KCCQ-OS score and NT-proBNP concentration, were variable but correlated with NYHA class. An unmet treatment need remains among patients with LMNA-related DCM. NCT03439514.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14955","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T09:38:31Z","timestamp":1723714711000},"page":"4201-4208","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Characterization and Natural History of Patients with\n                    <i>LMNA<\/i>\n                    -Related Dilated Cardiomyopathy in the Phase 3 REALM-DCM Trial"],"prefix":"10.1093","volume":"11","author":[{"given":"Pablo","family":"Garcia-Pavia","sequence":"first","affiliation":[{"name":"Hospital Universitario Puerta de Hierro Majadahonda , Madrid ,","place":["Spain"]},{"name":"Instituto de Investigaci\u00f3n Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA) , Madrid ,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n en Red en Enfermedades Cardiovasculares (CIBERCV) , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal K.","family":"Lakdawala","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital , Boston, Massachusetts ,","place":["USA"]},{"name":"Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Sinagra","sequence":"additional","affiliation":[{"name":"Cardiothoracovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste , Trieste ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Ripoll-Vera","sequence":"additional","affiliation":[{"name":"Hospital Universitario Son Llatzer , Mallorca ,","place":["Spain"]},{"name":"Health Research Institute of the Balearic Islands (IdISBa) , Mallorca ,","place":["Spain"]},{"name":"Department of Medicine, University of the Balearic Islands , Mallorca ,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Fisiopatolog\u00eda de la Obesidad y Nutrici\u00f3n (CIBERobn), Institute of Health Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kia","family":"Afshar","sequence":"additional","affiliation":[{"name":"Intermountain Heart Institute , Salt Lake City, Utah ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia G.","family":"Priori","sequence":"additional","affiliation":[{"name":"Centro Nacional de Investigaciones Cardiovasculares (CNIC) , Madrid ,","place":["Spain"]},{"name":"IRCCS Istituti Clinici Scientifici Maugeri SpA SB of Pavia , Pavia ,","place":["Italy"]},{"name":"Department of Molecular Medicine, University of Pavia , Pavia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S.","family":"Ware","sequence":"additional","affiliation":[{"name":"National Heart & Lung Institute and MRC London Institute of Medical Sciences, Imperial College London , London ,","place":["UK"]},{"name":"Royal Brompton & Harefield Hospitals, Guy's and St Thomas\u2019 NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Owens","sequence":"additional","affiliation":[{"name":"University of Pennsylvania Heart and Vascular Center , Philadelphia, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihua","family":"Li","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , Collegeville, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franca S.","family":"Angeli","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , Collegeville, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry","family":"Elliott","sequence":"additional","affiliation":[{"name":"University College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calum A.","family":"MacRae","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital , Boston, Massachusetts ,","place":["USA"]},{"name":"Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Judge","sequence":"additional","affiliation":[{"name":"Cardiovascular Genetics, Medical University of South Carolina , Charleston, South Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,15]]},"reference":[{"key":"2026012113114771100_ehf214955-bib-0001","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1056\/nejm199912023412302","article-title":"Missense mutations in the rod domain of the lamin A\/C gene as causes of dilated cardiomyopathy and conduction-system disease","volume":"341","author":"Fatkin","year":"1999","journal-title":"N Engl J Med"},{"key":"2026012113114771100_ehf214955-bib-0002","doi-asserted-by":"publisher","DOI":"10.12659\/msm.924576","article-title":"Identification of target genes and transcription factors in mice with LMNA-related dilated cardiomyopathy by integrated bioinformatic analyses","volume":"26","author":"Zhou","year":"2020","journal-title":"Med Sci Monit"},{"key":"2026012113114771100_ehf214955-bib-0003","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.3389\/fphys.2018.01356","article-title":"Role of lamin A\/C gene mutations in the signaling defects leading to cardiomyopathies","volume":"9","author":"Gerbino","year":"2018","journal-title":"Front Physiol"},{"key":"2026012113114771100_ehf214955-bib-0004","doi-asserted-by":"publisher","first-page":"4325","DOI":"10.1093\/hmg\/dds265","article-title":"Abnormal p38\u03b1 mitogen-activated protein kinase signaling in dilated cardiomyopathy caused by lamin A\/C gene mutation","volume":"21","author":"Muchir","year":"2012","journal-title":"Hum Mol Genet"},{"key":"2026012113114771100_ehf214955-bib-0005","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.cardfail.2013.03.001","article-title":"Temporal relationship of conduction system disease and ventricular dysfunction in LMNA cardiomyopathy","volume":"19","author":"Brodt","year":"2013","journal-title":"J Card Fail"},{"key":"2026012113114771100_ehf214955-bib-0006","volume-title":"GeneReviews","author":"Hershberger","year":"2022"},{"key":"2026012113114771100_ehf214955-bib-0007","doi-asserted-by":"publisher","first-page":"761","DOI":"10.3389\/fphys.2020.00761","article-title":"The broad spectrum of LMNA cardiac diseases: From molecular mechanisms to clinical phenotype","volume":"11","author":"Crasto","year":"2020","journal-title":"Front Physiol"},{"key":"2026012113114771100_ehf214955-bib-0008","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s11886-019-1224-7","article-title":"Lamin A\/C cardiomyopathy: Implications for treatment","volume":"21","author":"Chen","year":"2019","journal-title":"Curr Cardiol Rep"},{"key":"2026012113114771100_ehf214955-bib-0009","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1093\/eurheartj\/ehx596","article-title":"Lamin A\/C cardiomyopathy: Young onset, high penetrance, and frequent need for heart transplantation","volume":"39","author":"Hasselberg","year":"2018","journal-title":"Eur Heart J"},{"key":"2026012113114771100_ehf214955-bib-0010","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/s0735-1097(02)02954-6","article-title":"Natural history of dilated cardiomyopathy due to lamin A\/C gene mutations","volume":"41","author":"Taylor","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2026012113114771100_ehf214955-bib-0011","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.jacc.2019.06.072","article-title":"Genetic risk of arrhythmic phenotypes in patients with dilated cardiomyopathy","volume":"74","author":"Gigli","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026012113114771100_ehf214955-bib-0012","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s11886-019-1236-3","article-title":"Risk stratification for sudden cardiac death in non-ischaemic dilated cardiomyopathy","volume":"21","author":"Akhtar","year":"2019","journal-title":"Curr Cardiol Rep"},{"key":"2026012113114771100_ehf214955-bib-0013","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.ijcard.2012.09.118","article-title":"Lamin A\/C mutation is independently associated with an increased risk of arterial and venous thromboembolic complications","volume":"168","author":"van Rijsingen","year":"2013","journal-title":"Int J Cardiol"},{"key":"2026012113114771100_ehf214955-bib-0014","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1016\/j.jacc.2021.08.039","article-title":"Association of genetic variants with outcomes in patients with nonischemic dilated cardiomyopathy","volume":"78","author":"Escobar-Lopez","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026012113114771100_ehf214955-bib-0015","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1016\/j.hrthm.2019.05.007","article-title":"2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy","volume":"16","author":"Towbin","year":"2019","journal-title":"Heart Rhythm"},{"key":"2026012113114771100_ehf214955-bib-0016","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11936-017-0520-z","article-title":"Lamin A\/C cardiomyopathies: Current understanding and novel treatment strategies","volume":"19","author":"Wang","year":"2017","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"2026012113114771100_ehf214955-bib-0017","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/ejhf.2463","article-title":"The response to cardiac resynchronization therapy in LMNA cardiomyopathy","volume":"24","author":"Sidhu","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012113114771100_ehf214955-bib-0018","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.123.011548","article-title":"REALM-DCM: A phase 3, multinational, randomized, placebo-controlled trial of ARRY-371797 in patients with symptomatic LMNA-related dilated cardiomyopathy","volume":"17","author":"Garcia-Pavia","year":"2024","journal-title":"Circ Heart Fail"},{"key":"2026012113114771100_ehf214955-bib-0019","volume-title":"Pfizer to discontinue development program for PF-07265803 for LMNA-related dilated cardiomyopathy [media release]","author":"Pfizer"},{"key":"2026012113114771100_ehf214955-bib-0020","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.122.003730","article-title":"Efficacy and safety of ARRY-371797 in LMNA-related dilated cardiomyopathy: A phase 2 study","volume":"16","author":"MacRae","year":"2023","journal-title":"Circ Genom Precis Med"},{"key":"2026012113114771100_ehf214955-bib-0021","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2217\/fca-2022-0099","article-title":"Plain language summary of publication of the safety and efficacy of ARRY-371797 in people with dilated cardiomyopathy and a faulty LMNA gene","volume":"19","author":"MacRae","year":"2023","journal-title":"Future Cardiol"},{"key":"2026012113114771100_ehf214955-bib-0022","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.amjcard.2022.08.001","article-title":"Long-term efficacy and safety of ARRY-371797 (PF-07265803) in patients with lamin A\/C-related dilated cardiomyopathy","volume":"183","author":"Judge","year":"2022","journal-title":"Am J Cardiol"},{"key":"2026012113114771100_ehf214955-bib-0023","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2217\/fca-2022-0125","article-title":"Long-term effectiveness of ARRY-371797 in people with dilated cardiomyopathy and a faulty LMNA gene: A plain language summary","volume":"19","author":"Judge","year":"2023","journal-title":"Future Cardiol"},{"key":"2026012113114771100_ehf214955-bib-0024","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1016\/j.jacc.2016.08.058","article-title":"Long-term arrhythmic and nonarrhythmic outcomes of lamin A\/C mutation carriers","volume":"68","author":"Kumar","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026012113114771100_ehf214955-bib-0025","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2016-000474","article-title":"Clinical disease presentation and ECG characteristics of LMNA mutation carriers","volume":"4","author":"Ollila","year":"2017","journal-title":"Open Heart."},{"key":"2026012113114771100_ehf214955-bib-0026","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10215075","article-title":"Clinical features of LMNA-related cardiomyopathy in 18 patients and characterization of two novel variants","volume":"10","author":"Ferradini","year":"2021","journal-title":"J Clin Med"},{"key":"2026012113114771100_ehf214955-bib-0027","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00109-004-0589-1","article-title":"Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: Do lamin A\/C mutations portend a high risk of sudden death?","volume":"83","author":"van Berlo","year":"2005","journal-title":"J Mol Med (Berl)"},{"key":"2026012113114771100_ehf214955-bib-0028","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.rec.2020.03.026","article-title":"Risk predictors in a Spanish cohort with cardiac laminopathies. The REDLAMINA registry","volume":"74","author":"Barriales-Villa","year":"2021","journal-title":"Rev Esp Cardiol (English Edition)"},{"key":"2026012113114771100_ehf214955-bib-0029","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2018-000915","article-title":"Lamin mutation location predicts cardiac phenotype severity: Combined analysis of the published literature","volume":"5","author":"Captur","year":"2018","journal-title":"Open Heart"},{"key":"2026012113114771100_ehf214955-bib-0030","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.jacc.2008.06.044","article-title":"Long-term outcome and risk stratification in dilated cardiolaminopathies","volume":"52","author":"Pasotti","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026012113114771100_ehf214955-bib-0031","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jacc.2011.08.078","article-title":"Risk factors for malignant ventricular arrhythmias in lamin A\/C mutation carriers","volume":"59","author":"van Rijsingen","year":"2012","journal-title":"J Am Coll Cardiol"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/6\/4201\/64516848\/eschf_11_6_4201.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/6\/4201\/64516848\/eschf_11_6_4201.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:13:50Z","timestamp":1769019230000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/11\/6\/4201\/8269333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,15]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,8,15]]},"published-print":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14955","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,8,15]]},"assertion":[{"value":"2023-10-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}